According to the Psoriasis Longitudinal Assessment and Registry (PSOLAR), malignancy risk increased with long-term exposure to TNF-α inhibitors, but not with exposure to methotrexate or ustekinumab, anti-interleukin 12/23 antibody [6]. Here, TNF is linked to psoriasis.